Financials data is unavailable for this security.
View more
Year on year Grand Pharmaceutical Group Ltd had net income fall -9.59% from 2.08bn to 1.88bn despite a 10.12% increase in revenues from 9.56bn to 10.53bn. An increase in the selling, general and administrative costs as a percentage of sales from 35.28% to 36.66% was a component in the falling net income despite rising revenues.
| Gross margin | 59.00% |
|---|---|
| Net profit margin | 22.92% |
| Operating margin | 28.60% |
| Return on assets | 10.25% |
|---|---|
| Return on equity | 15.97% |
| Return on investment | 14.21% |
More ▼
Cash flow in HKDView more
In 2023, cash reserves at Grand Pharmaceutical Group Ltd fell by 104.31m. However, the company earned 2.42bn from its operations for a Cash Flow Margin of 23.03%. In addition the company used 515.75m on investing activities and also paid 1.89bn in financing cash flows.
| Cash flow per share | 0.8231 |
|---|---|
| Price/Cash flow per share | 5.49 |
| Book value per share | 4.43 |
|---|---|
| Tangible book value per share | 3.49 |
More ▼
Balance sheet in HKDView more
| Current ratio | 1.29 |
|---|---|
| Quick ratio | 1.09 |
| Total debt/total equity | 0.2906 |
|---|---|
| Total debt/total capital | 0.2232 |
More ▼
Growth rates in HKD
Year on year, growth in dividends per share increased 85.71% while earnings per share excluding extraordinary items fell by -8.70%. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 2.73% |
|---|---|
| Div growth rate (5 year) | 24.77% |
| Payout ratio (TTM) | 37.58% |
| EPS growth(5 years) | 15.13 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 1.91 |
More ▼
